Therapeutic effect of genetically engineered mesenchymal stem cells in rat experimental leptomeningeal glioma model

Cancer Letters
Chunyu GuHiroki Namba

Abstract

Disseminating disease of high grade gliomas is difficult to treat. We examined the therapeutic effect of intrathecal administration of mesenchymal stem cells transduced with herpes simplex virus-thymidine kinase gene (MSCtk) followed by systemic ganciclovir (GCV) administration in rat experimental leptomeningeal glioma model. First, to examine in vivo bystander effect, rats were intrathecally co-injected with a mixture of MSCtk and C6 cells and then, intraperitoneally administered with GCV or saline for 10days (co-injection model). Next, to examine the therapeutic effect of MSCtk/GCV therapy, MSCtk cells were intrathecally administered 1day after C6 injection and then, GCV or saline was administered (treatment model). GCV administration significantly reduced tumor size on day 14 both in the co-injection model (0.41+/-0.22 vs. 3.10+/-0.97mm(2), p<0.01) and in the treatment model (0.73+/-.29 vs. 2.84+/-0.82mm(2), p<0.01). Survival was also significantly prolonged in GCV group both in the co-injection model (29.2+/-3.3 vs. 18.8+/-0.8days, p<0.001) and in the treatment model (21.5+/-1.5 vs. 17.2+/-0.5days, p<0.001). This study provided a novel treatment strategy for leptomeningeal glioma dissemination using intrathecal MSCtk inject...Continue Reading

References

Jun 21, 1995·Journal of the National Cancer Institute·K HiyamaJ W Shay
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·G C KopenD G Phinney
Nov 9, 2000·Proceedings of the National Academy of Sciences of the United States of America·K S AboodyE Y Snyder
Jan 15, 2004·The Neurologist·Kevin J Klos, Brian Patrick O'Neill
Aug 4, 2004·Cancer Research·Karin StaflinMagnus Lindvall
Jul 11, 2006·Stem Cells·Annette SchmidtWilhelm Bloch
Nov 22, 2007·Science·Junying YuJames A Thomson
Feb 3, 2009·Carcinogenesis·Fabian L MuehlbergEckhard U Alt
Nov 1, 2003·Expert Review of Neurotherapeutics·Moneeb EhteshamJohn S Yu
Nov 4, 2009·International Journal of Oncology·Shinji AmanoHiroki Namba

❮ Previous
Next ❯

Citations

Nov 27, 2010·Journal of Neuro-oncology·John D HeissZvi Ram
Apr 26, 2012·Stem Cells and Development·Qi BaoChristiane J Bruns
Jan 13, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Faranak Salman NouriArash Hatefi
Oct 2, 2012·Stem Cell Research·Shaoyi LiHiroki Namba
Jul 28, 2016·Stem Cells and Development·Adam NowakowskiBarbara Lukomska
Jul 14, 2017·Journal of Cellular Physiology·Rana Moradian TehraniHamed Mirzaei
Aug 15, 2020·Frontiers in Bioengineering and Biotechnology·Amirhesam BabajaniHassan Niknejad
Jul 1, 2010·Experimental and Therapeutic Medicine·Yun GaoHiroki Namba
Feb 14, 2021·Materials Science & Engineering. C, Materials for Biological Applications·Barbara Blanco-FernandezElisabeth Engel
Jan 5, 2021·The Oncologist·Cristina BirzuAhmed Idbaih

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.